Elsersy Hazem E, Zahran Magdy A H, Elbakry Abd-Elazeem, Abd-Elwahab Mohamed, Ahmed Mohamed Milegy, Elgandy Mohamed Salah, Mohammed Eman H M, Elewa Nourhan M
Department of Anesthesia and Intensive Care, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt.
Organic Chemistry Department, Faculty of Science, Menoufia University, Shebin El-Kom, Egypt.
Front Med (Lausanne). 2022 Apr 19;9:863917. doi: 10.3389/fmed.2022.863917. eCollection 2022.
The COVID-19 pandemic is still posing challenging health and economic problems. Effective broad-spectrum antiviral therapy is urgently needed for the control of early SARS-CoV-2 infection to limit its spread and mutations. In this randomized placebo-controlled clinical study, we tested the effects of intranasal and oropharyngeal delivery of a compound of povidone-iodine 0.5% and glycyrrhizic acid 2.5 mg/ml on the laboratory (PCR) and clinical recovery from SARS-CoV-2 patients and their household contacts. 353 patients suspected of having COVID-19 infection were screened by chest CT and nasopharyngeal swab tests (PCR). 200 patients were randomly allocated to two equal groups: treatment and placebo groups. Treatment accelerated the recovery of PCR on days 4, 7, and 10, as evidenced by PCR-positive patients (70, vs. 99%, 20 vs. 65%, 1 vs. 10%) in both the treated and placebo groups, respectively. Treatment enhanced the early recovery of symptoms [day 7.6 ± 2 (CI 7:8.3) vs. 8.9 ± 2 (CI 8.3:9.6)]. Treatment promoted early recovery of anosmia and ageusia [5.6 ± 1 (CI, 4.8:6.4) vs. 11 ± 3 days, (CI, 10.8:12)] in both the treated and control groups ( < 0.0001). There was a notable reduction in transmission of the virus among the household close contacts in the treatment group (4%) vs. 76% in the placebo group. Combined PVI-GA nasal and oropharyngeal spray accelerates both laboratory and clinical recovery of SARS-CoV-2 infected patients in the early phases of the disease and reduces the household spread of the virus; thus, it may play an important role in controlling coronavirus outbreaks.
https://pactr.samrc.ac.za, PACTR202101875903773.
新冠疫情仍在带来具有挑战性的健康和经济问题。迫切需要有效的广谱抗病毒疗法来控制早期新冠病毒感染，以限制其传播和变异。在这项随机安慰剂对照临床研究中，我们测试了经鼻和经口咽递送0.5%聚维酮碘与2.5毫克/毫升甘草酸的化合物对新冠患者及其家庭接触者的实验室（PCR）检测结果及临床康复情况的影响。通过胸部CT和鼻咽拭子检测（PCR）对353名疑似感染新冠病毒的患者进行了筛查。200名患者被随机分为两组，每组人数相等：治疗组和安慰剂组。治疗加快了第4天、第7天和第10天PCR检测结果的恢复，治疗组和安慰剂组中PCR阳性患者比例分别为（70%对99%、20%对65%、1%对10%），这证明了这一点。治疗促进了症状的早期恢复[第7.6±2（CI 7:8.3）天对8.9±2（CI 8.3:9.6）天]。治疗促进了治疗组和对照组嗅觉减退和味觉减退的早期恢复[5.6±1（CI，4.8:6.4）天对11±3天，（CI，10.8:12）天]（<0.0001）。治疗组家庭密切接触者中的病毒传播显著减少（4%），而安慰剂组为76%。聚维酮碘-甘草酸联合鼻用和口咽喷雾剂可加快新冠病毒感染患者疾病早期的实验室检测结果恢复和临床康复，并减少病毒在家庭中的传播；因此，它可能在控制冠状病毒疫情中发挥重要作用。
